Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach by Ricardi, Umberto et al.
Clinical applications of stereotactic radiation
therapy for oligometastatic cancer patients:
a disease-oriented approach
Umberto Ricardi*, Serena Badellino and Andrea Riccardo Filippi
Department of Oncology, University of Torino, Via Genova 3, 10126 Torino, Italy
*Corresponding author. Radiation Oncology, Department of Oncology, University of Torino, Via Genova 3, 10126 Torino, Italy.
Tel: + 39-011-670-5350; Fax: + 39-011-633-6614; Email: umberto.ricardi@unito.it
Received September 28, 2015; Revised December 2, 2015; Accepted December 10, 2015
ABSTRACT
Oligometastases from solid tumors are currently recognized as a distinct clinical entity, corresponding to an inter-
mediate state between local and widespread disease. It has been suggested that local ablative therapies (including
surgery, radiofrequency ablation and radiation therapy) play an important role in this setting, in combination or
not with systemic therapies, particularly in delaying disease progression and hopefully in increasing the median sur-
vival time. Stereotactic body radiation therapy (SBRT) rapidly emerged in recent years as one of the most effective
and less toxic local treatment modalities for lung, liver, adrenal, brain and bone metastases. The aim of this review
was to focus on its clinical role for oligometastatic disease in four major cancer subtypes: lung, breast, colorectal
and prostate. On the basis of the available evidence, SBRT is able to provide high rates of local tumor control
without significant toxicity. Its global impact on survival is uncertain; however, in specific subpopulations of oligo-
metastatic patients there is a trend towards a significant improvement in progression-free and overall survival rates;
these important data might be used as a platform for clinical decision-making and establish the basis for the
current and future prospective trials investigating its role with or without systemic treatments.
KEYWORDS: stereotactic body radiotherapy, stereotactic ablative radiotherapy, oligometastases, radiotherapy,
radiosurgery
INTRODUCTION
Though metastases are generally widely disseminated, a minimal
metastatic state has been recently recognized, with a distinct natural
history and an intermediate prognosis between that of localized and
metastatic disease [1]. In 1995, S. Hellman and R. Weichselbaum first
coined the term ‘oligometastases’: the definition of such a state came
after years of research on the natural history of human solid tumors,
especially breast cancer [2]. Within this framework, they also devel-
oped the idea that local treatments such as radiation therapy would
probably have an increasing role, especially in those patients with
slowly progressing cancer. Several years later, methods of morpho-
logical and metabolic imaging have improved dramatically, new sys-
temic therapies are able to prolong survival and the oligometastatic
state is increasingly encountered in most common tumors, including
lung, breast, colorectal and prostate cancer. A combination of local
therapies with systemic treatments at different time-points in the
natural history of the disease is currently being offered to patients in a
number of institutions worldwide, both in clinical studies and outside
experimental trials [3–6]. Recent data suggest that oligometastases
may be relatively common, at least among certain tumour types, for
example breast cancer [7]. It is accepted that the oligometastatic state
can occure in three categories of patients: patients who present with
oligometastatic disease at diagnosis, those with oligoprogressive
disease after cytoreductive therapy, and those with oligorecurrent
disease after curative locoregional therapy [8]. The number of metas-
tases generally accepted as truly ‘oligo’ are less than or equal to five in
no more than three different organs, even if the definition can be dis-
cussed and adapted to specific clinical presentations. Radiotherapy
may play a unique role in this scenario, as the technological advances
in the field of radiation oncology allow for rapid non-invasive delivery
of very high radiation doses to specific sites. Stereotactic body radi-
ation therapy (SBRT) or stereotactic ablative radiotherapy (SABR)
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has been extensively investigated in recent years, showing high local
control rates (LCRs) and promising progression-free survival esti-
mates in selected metastatic patients, at the price of a very limited tox-
icity [5]. By the term SBRT, we currently refer to a ‘philosophy’ of
cancer treatment with highly focused radiation doses in one or few
sessions (less than or equal to eight), administered with ablative
intent [9]. Figure 1 depicts the most common treated sites.
However, determining the clinical advantages or superior survival
of this strategy when compared with systemic therapy or observation
alone is challenging because of the predominantly retrospective nature
of existing data; this has raised substantial concerns about positive selec-
tion biases in reported series (better performance status, longer
disease-free interval, smaller metastatic burden, less aggressive
course). In many cases it is unclear whether better than expected out-
comes are seen due to the efficacy of the ablative treatments or to
patient selection (more indolent tumor biology) [10]. Prognostic
data are lacking for adequate patient selection; the ability to predict
rapidly versus slowly progressive disease would be of major import-
ance for the design of customized therapeutic strategies as well as for
prospective clinical trials. In general, evidence supporting the concept
of prolongation of progression-free survival (and sometimes overall
survival [OS]) by the combined use of systemic and local therapies
comes from observational cohort studies using surgery and/or radio-
therapy taken together. Perhaps the best evidence for a local ablative
approach for oligometastatic disease comes from surgery for lung or
liver oligometastases from colorectal cancer (CRC) performed
sequentially following systemic treatment [11]. However, in recent
years only limited prospective data from pioneer researchers has
become available.
The purpose of the present review is to focus on the role of SBRT
as local ablative therapy for most common oligometastatic cancer
subtypes, with the aim of discussing its results and possible applica-
tions as a disease-specific local therapy option either with or without
systemic therapies.
SBRT FOR OLIGOMETASTATIC NON–SMALL
CELL LUNG CANCER
Oligometastatic non–small cell lung cancer (NSCLC), presenting
with one to five synchronous or metachronous metastatic lesions, has
recently been considered a distinct disease state [12]. Locally ablative
therapies are often used for such clinical presentations; however, the
subset of patients who may benefit from these interventions at meta-
static sites or at the primary lesion has not been conclusively identi-
fied. These issues are reflected by the heterogeneous survival
outcomes reported in several retrospective and a limited number of
prospective studies on oligometastatic lung cancer [4]. A single-arm
Phase II study enrolled 39 patients presenting with Stage IV disease
with less than four synchronous sites of distant metastasis [13]. The
primary lesion was treated with radiotherapy alone or in combination
with chemotherapy, and all sites of distant metastases were treated
with surgery or SBRT. The median OS was 13.5 months, though six
patients were progression-free after 2 years. The median progression-
free survival (PFS) was 12.1 months. An individual patients’ data
meta-analysis of outcome of SBRT in oligometastatic NSCLC with
one to five synchronous or metachronous metastases treated with sur-
gical metastectomy, SBRT/radiosurgery, or radical external-beam
radiotherapy (and curative treatment of the primary lung cancer)
showed a median survival time of 19 months among patients with
controlled primary tumors. Aggressive treatment to the primary
tumor and metastases improved OS, supporting the hypothesis that
oligometastatic NSCLC represents a clinically distinct and potentially
curable disease. Collen et al. also reported on a Phase II prospective
study of SBRT to primary tumor and metastatic locations in oligome-
tastatic NSCLC [14]. SBRT could be delivered after induction
chemotherapy, but after radiation no further treatment was given
until progression. With 26 patients enrolled and 16.4 months of
median follow-up time, a total of 87 sites were irradiated, including
48 metastases. With 30% showing complete metabolic response and
30% showing partial response rate, the median OS was 23 months,
with 67% of patients alive at 1 year. The median progression-free sur-
vival (PFS) was 11.2 months.
Recently, an individual patient data meta-analysis on oligometa-
static lung cancer patients showed that factors predictive of OS were:
synchronous versus metachronous metastases (P < 0.001), N-stage
(P = 0.002), and adenocarcinoma histology (P = 0.036); the model
remained predictive in the validation set (c-statistic = 0.682). After
recursive partitioning analysis (RPA), three risk groups were identi-
fied: low-risk, metachronous metastases (5-year OS, 47.8%); inter-
mediate-risk, synchronous metastases and N0 disease (5-year OS,
36.2%); and high-risk, synchronous metastases and N1/N2 disease
(5-year OS, 13.8%) [15].
The majority of published studies on oligometastatic NSCLC
actually describe the outcomes for patients with resected solitary
brain metastases. As an alternative to surgery, stereotactic brain radio-
surgery (SRS) has the advantage of being able to treat unresectableFig. 1. Metastatic sites treatable with stereotactic radiotherapy.
2 • U. Ricardi et al.
metastases, easily treating multiple tumors in different regions of the
CNS in a single course, and imparting acceptable rates of local
control for small- to medium-sized tumors using a single modality
[16]. Flannery et al. described the outcomes for a cohort of 42
patients treated for a solitary, synchronous brain metastasis from
NSCLC [17]. The patients had Stage I–III thoracic disease, and
slightly more than half (62%) were treated definitively in the chest
area with chemoradiotherapy with or without surgery. For 26 patients
whose thoracic disease was treated with radical intent, the median OS
was ∼26 months, twice that of patients whose thoracic disease was
treated with chemotherapy alone. All patients received brain SRS. In
all but five cases, the patients died due to progression of the disease
outside the CNS, suggesting that an aggressive local approach to
treating brain metastases in patients who can tolerate definitive treat-
ment for their primary disease may be appropriate. The median OS
for the whole population was 18 months. It should also be noted that,
in the previously cited prospective trial by De Ruysscher et al. [13],
most of the enrolled patients were oligometastatic for a single brain
lesion, with encouraging results in terms of median OS of the whole
cohort and few long-term survivors.
SBRT was mostly used as an effective means of treating pulmon-
ary oligometastases [4]. In the case of NSCLC, it is often not possible
to determine whether one or both lung lesions represent primary
lesions. If one or more lesions are presumed to be metastatic, accord-
ing to the AJCC 2009, lesions in the ipsilateral or contralateral lung
signify T4 or M1a classifications, respectively, in both cases indicating
a better prognosis than extrapulmonary metastatic disease [18].
De Rose et al. recently reported on a series of 60 patients affected
with lung oligometastases from NSCLC with controlled primary
tumors: 90 lung lesions were treated, and with a median follow-up
time from diagnosis of 28 months the local control at 2 years was
88.9%, with OS rates at 1 and 2 years of 94.5% and 74.6%, respect-
ively. The median PFS was 32.2 months, and the median OS was
32.1 months [19].
Moreover, small retrospective series have described the outcomes
following resection of solitary adrenal metastases in oligometastatic
NSCLC. Interestingly, in a surgical series, a comparison of median
survival favored metachronous over synchronous metastases (12
months versus 31 months); however, 5-year survival rates were com-
parable, at ∼25% [20]. A recent report described the use of SBRT for
treating 13 patients with a solitary adrenal metastasis from NSCLC
using doses ranging from 20 to 40 Gy delivered in five fractions. The
median PFS was 12 months, the median OS was 23 months, and the
crude rate of local control was 77% [21]. Two recent reports, unre-
stricted to NSCLC adrenal metastases but with the majority of
patients included being affected by oligometastatic lung cancer,
LCRss were promising, but PFS rates were disappointing [22, 23].
Patients with metastatic lung cancer driven by epidermal growth
factor receptor (EGFR) mutations or anaplastic lymphoma kinase
(ALK) gene rearrangements, treated with the tyrosine-kinase inhibi-
tors (TKIs), represent a distinct group. These patients have superior
survival rates compared with patients not carrying these mutations
and treated with standard cytotoxic therapies [24–27]. Weickhardt
et al. reported a single institution retrospective study of 25 patients
who developed oligoprogressive disease in the CNS alone or with
four or fewer extracranial metastases when on treatment with either
erlotinib or crizotinib monotherapy [28]. Patients were treated with
SBRT, SRS, whole brain radiotherapy, or surgery and maintained on
the same drug. This strategy was associated with a median of 6 add-
itional months before a second progression. In particular, with a
median follow-up of 20 months, the median PFS (from local treat-
ment to second progression) was 6.2 months. In a similar study, 18
patients with EGFR-mutant, non-CNS, oligoprogressive disease
received ablative treatment while continuing TKI monotherapy. The
median time to progression was 10 months and the median OS fol-
lowing first local treatment was 41 months [29]. Iyengar et al. recently
reported on a Phase II trial on SBRT and erlotinib in patients previ-
ously treated with chemotherapy [30]. The patients included had less
than six extracranial metastatic sites, and those progressing after
SBRT were allowed to remain in the trial if progression occurred
outside the treatment field. A total of 24 patients were accrued, and
52 lesions treated, most commonly in the lung or mediastinum. The
trial met its primary endpoint, with a 69% rate of PFS at 6 months, a
median PFS of 14.7 months and a median OS of 20.4 months. The
pattern of progression was mainly at new sites (allowing for other
possible local ablative treatments). At the same time, Grade 3 toxicity
was not negligible (in particular, pulmonary toxicity), a possible con-
sequence of the combination. Given the paucity of data, despite these
encouraging results, SBRT and continuation of the same drug in oli-
goprogressive patients under treatment with TKIs is not presently
considered as a standard of care. Variations to this approach are
expected when new results from prospective trials will be available.
Table 1 summarizes the characteristics and results of the studies
using SBRT as metastasis-directed local therapy for oligometastatic
NSCLC.
Although the reported outcomes of these single-arm studies
appear promising, some caution is warranted. Many questions
remain, such as the influence of tumor biology, the use of biomarkers
for patient selection, and the effect of novel systemic therapies,
including immunotherapy [10, 31]. As for other cancer subtypes,
emerging therapies could lead to a scenario where the better control
of occult disease will possibly amplify the effect of local ablative ther-
apies on visible deposits.
SBRT FOR OLIGOMETASTATIC BREAST
CANCER
Breast cancer is probably the first model used to illustrate the natural
history of solid tumors, and the mechanisms underlying the meta-
static spread [2]. Therefore, it is also one of the cancer subtypes
where the hypothesis of oligometastases was first formulated, and it
served as a model to illustrate the rationale for the use of local therap-
ies to a few metastatic sites, in combination with systemic agents [7].
Over the past years, while systemic therapies have improved the
control of subclinical breast cancer metastases and prolonged progres-
sion-free intervals [32], most long-term survivors have received
aggressive local therapies following systemic therapy [33]. This is
likely due to the fact that patients with oligometastatic disease usually
progress in sites of known metastases, and not in new metastatic loca-
tions [7]. Very few studies have been published on the use of SBRT
for oligometastatic breast cancer patients. The University of Roches-
ter researchers published seminal and most relevant data regarding
the use of SBRT in oligometastatic breast cancer [34–36]. In particu-
lar, a pooled analysis of women treated with two subsequent
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Table 1. Studies investigating the use of SBRT in oligometastatic non–small cell lung cancer
Study Patients Eligibility criteria Study design Site of metastases Therapy Median
follow-up
(months)
Median PFS
(months)
Median OS
(months)
Other therapy
(percentage)
De Ruysscher
et al. [13]
39 Stage IV with <5
metastases
single-arm
Phase II
brain, bone, adrenal
gland
SRS/SBRT/
surgery
27.7 12.1 13.5 chemoradiotherapy
for primary tumor
(92%)
Collen et al. [15] 26 Stage IV with <5
metastases
single-arm
Phase II
lung, bone, adrenal
gland, brain,
liver, lymph
nodes
SBRT 16.4 11.2 23 induction
chemotherapy
(65%)
Flannery et al. [17] 42 synchronous solitary
brain metastases
retrospective
observational
solitary brain SRS 64.5 NR 18 local thoracic therapy
(62%)
De Rose et al. [19] 60 synchronous or
metachronous lung
metastases with
controlled primary
tumor
retrospective
observational
lung SBRT 28 32.2 32.1 chemotherapy (49%)
Holy et al. [21] 13 synchronous or
metachronous
adrenal metastases
retrospective
observational
adrenal glands SBRT 12 12 23 NR
Weickhardt
et al. [28]a
25 oligoprogression
under TKIs
subgroup analysis
of prospective
trial
brain, bone, lung,
adrenal gland,
liver
SBRT and
surgery
20 6.2 (from treatment
to second
progression)
NR NA
Yu et al. [29]a 18 extracranial
oligoprogression
under TKIs
subgroup analysis
of prospective
trial
lung, lymph nodes,
adrenal glands
SBRT, surgery,
RFA and TKIs
NR 10 41 NA
Iyengar et al. [30]a 24 oligoprogression after
first line
chemotherapy
(<6 metastases)
single-arm
Phase II
lung, lymph nodes,
adrenal glands,
bone, liver
SBRT + erlotinib 11.6 14.7 20.4 previous chemotherapy
(100%)
aCombination of local therapies and TKIs. RFA = radiofrequency ablation, SRS = stereotactic radiosurgery, SBRT = stereotactic body radiation therapy, TKIs = tyrosine-kinase inhibitors, PFS = progression-free survival, OS = overall
survival, NA = not applicable, NR = not reported.
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protocols for oligometastatic cancer [35] showed promising results:
the 4-year OS rate was 59% and the 4-year PFS rate was 38%, with
almost 90% of metastases locally controlled by radiation therapy. The
median PFS was 23 months, while median OS was not reached
(Table 2). A plateau was evident in the Kaplan–Meier projection
after 40 months. Paradoxically, the increased use of SBRT for treating
oligometastatic cancers (and particularly breast cancer) made it diffi-
cult to design and conduct prospective clinical trials, because in most
Centers SBRT is offered as a ‘routine’ option; this was evident from a
recent international survey, in which it was found that 83% of radi-
ation oncologists were offering SBRT to oligometastatic cancer
patients after 2005 and more than half of the remaining were plan-
ning to start in the next 3 years [37]. At the same time, especially for
breast cancer, where the apparent benefit of this strategy is greater, a
lack of evidence is perceived and trials are ongoing: NRG Oncology
is conducting a Phase I dose de-escalation study (NRG BR001) in
which breast, lung and prostate cancer patients with two metastases
in close proximity or those with three to four metastases will receive
radiation to all known sites of disease, with dose selected on the basis
of tumor location and the potential for normal tissue toxicity. An
alternative approach, comparing SBRT at fixed dose levels plus stand-
ard systemic therapy versus standard systemic therapy plus/minus
palliative radiotherapy is used in the COMET trial, which includes
different cancer subtypes (SABR COMET, NCT01446744). NRG
Oncology is also conducting a randomized Phase II trial (NRG
BR002) on oligometastatic breast cancer patients to determine
whether the addiction of ablative therapy to all known metastases is
superior to standard therapy alone in terms of PFS (with the aim of
planning a Phase III study with OS as the primary endpoint if the
results are positive). As for other oligometastatic tumors, the identifi-
cation of favorable/unfavorable prognostic groups remains challen-
ging. From surgical series, known favorable prognostic factors are
estrogen-receptor positivity, response to systemic therapies, fewer and
smaller metastases and longer disease-free interval [38]. Patients
receiving ablative radiotherapy for bone-only metastases, single
metastases and stable or responding metastases have shown improved
outcomes [35].
SBRT FOR OLIGOMETASTATIC COLORECTAL
CANCER
CRC is one of the tumors that most often present oligorecurrence,
most commonly in the liver and lung. Surgical removal of liver and
lung lesions is apparently associated with better survival, despite the
absence of controlled randomized data. Liver resection may achieve
5-year OS rates in the range of 37–58% [39–42]; also, pulmonary
resection is able to achieve 5-year survival rates in the range of 38–
50% [43, 44]. Approximately 70–90% of CRC metastatic patients,
however, are unresectable [45]. Radiofrequency ablation (RFA)
directed to liver metastases has been used as an alternative to surgical
resection, but the use of RFA has limitations related to the size and
location of the target lesions [46–48]. Schlijper et al. reviewed the
clinical reports published as at 2011 on the application of surgery,
RFA or SBRT in patients with pulmonary oligometastases from
CRC, selected for a minimum follow-up of 24 months and a
minimum inclusion of 50 patients. Twenty-three surgical series ful-
filled the selection criteria, four of which were prospective. Survival
rates for surgery were 64–88% at 2 years and 29–71.2% at 5 years.
Limited data were available for RFA, with survival rates ranging from
64 to 73% at 2 years and 34.9 to 45% at 5 years [49]. No studies on
SBRT fulfilled the selection criteria.
However, SBRT was investigated in the treatment of liver and
lung metastases with promising results, using either a single dose or a
small number of fractions, in studies unrestricted to CRC patients
[50–52]. In particular, for liver metastases, results of prospective
trials showed very favorable results in terms of local control and PFS
[53, 54].
Few studies are focused on the use of SBRT for oligometastatic
CRC patients. Kim et al. first reported on 13 cases of isolated pul-
monary metastasis from CRC treated using SBRT. All patients under-
went chemotherapy for salvage treatment. The median follow-up was
28 months; the 3-year OS and PFS rates were 64.7% and 11.5%,
respectively [55].
Takeda et al. analyzed 15 patients with lung oligometastases from
CRC, 19 from other origins, and 183 primary lung cancers. The
primary endpoint of that study was to compare local control. The
median follow-up for the CRC cohort was 29 months, for lung metas-
tases from other origins 15 months and for primary NSCLC 24
months. The 1-year and 2-year LCRs for CRC lung metastases and
from other origins were 80% and 72%, and 94% and 94%, respect-
ively. The LCR for CRC metastases was significantly worse than from
the other origins and primary lung cancers with pathological and clin-
ical diagnosis (P < 0.05, P < 0.0001 and P < 0.005, respectively) [56].
In a recent retrospective cohort study including 40 patients
treated with SBRT at the time of first lung progression, with a median
follow-up of 20 months, the median PFS and OS were 8 and 46
months, respectively [57]. These results are quite promising in view
of the negative selection for factors such as age or comorbidities
typical of the non-surgical population, because the reported 2-year
OS after surgery is in the range of 64–88%. Qiu et al. also reported on
a mono-institutional cohort of 65 patients treated for CRC lung
metastases: the median OS was 20.3 months and the median PFS
was 5.7 months. Nearly all (98%) patients developed distant progres-
sion. Extra lung and liver involvement at the time of initial metastases
(hazard ratio 2.10) and extra lung involvement at the time of SBRT
(hazard ratio 2.67) were the only independent predictors of OS [58].
A prospective observational series by Comito et al. included 82
patients with one to three inoperable metastases confined to one
organ (liver or lung), treated with SBRT for a total of 112 lesions.
The median follow-up was 24 months, and the median OS was 32
months; the OS rate at 1, 2 and 3 years was 85%, 65% and 43%,
respectively. Univariate analysis showed a correlation only between
OS and cumulative tumor volume >3 cm (P < 0.02). The median
PFS was 14 months, with a PFS rate of 56% and 40% at 1 and 2
years, respectively [59]. Table 2 summarizes the results of the studies
investigating the use of SBRT for CRC oligometastases.
As for other oligometastatic scenarios, there is a lack of prospect-
ive controlled data comparing surgery or stereotactic radiotherapy
versus observation or systemic therapy alone. The ongoing PulMICC
trial (UK, clinicaltrials.gov identifier NCT01106261) is an example of
a feasibility study with the aim to determine whether it will be pos-
sible to recruit sufficient patients for a larger Phase III randomized
trial powered to detect statistical differences in OS between metasta-
sectomy and active monitoring. This trial is completing patient
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Table 2. Studies investigating the use of SBRT in oligometastatic breast and colorectal cancer
Study Patients Eligibility criteria Study design Site of metastases Therapy Median
follow-up
(months)
Median PFS
(months)
Median OS
(months)
Other therapy (percentage)
Breast cancer
Milano et al. [35] 40 <5 extracranial metastases subgroup analysis
of a prospective
Phase II trial
liver, lung, lymph
nodes, bone
SBRT NR 23 not reached adjuvant chemotherapy/
hormonal therapy (80%)
Colorectal cancer
Kim et al. [55] 13 isolated lung metastases retrospective
observational
lung SBRT 28 NR (PFS at
3 years:
11.5%)
NR (OS at
3 years:
64.7%)
chemotherapy (100%)
Takeda et al. [56] 15 lung oligometastases retrospective
observational
with LC as
primary endpoint
lung SBRT 29 NA (LC at
2 years:
72%)a
NA NA
Filippi et al. [57] 40 metachronous, at first lung
progression
retrospective
observational
lung SBRT 20 8 46 pre-post SBRT
chemotherapy (20%)
Qiu et al. [58] 65 synchronous/
metachronous lung
progression
retrospective
observational
lung SBRT 6.4 5.7 20.3 previous chemotherapy for
metastatic disease (69%)
Comito et al. [59] 82 1–3 lung or liver
metastases
retrospective
observational
lung, liver SBRT 24 14 32 pre-post SBRT
chemotherapy (95%)
aLocal control rates were compared with metastases from other origins and primary lung cancer, with statistically significant inferiority (P < 0.05). SRS = stereotactic radiosurgery, SBRT = stereotactic body radiation therapy,
PFS = progression-free survival, OS = overall survival, LC = local control, NA = not applicable, NR = not reported.
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recruitment, and will hopefully give us important information not
only on clinical endpoints (OS is the secondary endpoint), but also
on which patients are routinely offered surgery. The ORCHESTRA
trial (A Randomized Multicenter Clinical Trial for Patients with
Multi-Organ Colorectal Cancer Metastases Comparing the Combin-
ation of Chemotherapy and Maximal Tumor Debulking versus
Chemotherapy Alone, NCT 01792934) will also hopefully provide
useful clinical evidence.
SBRT FOR OLIGOMETASTATIC PROSTATE
CANCER
Available data on metastasis-directed therapies for oligometastatic
prostate cancer consists of small and heterogeneous studies, but a
recent systematic review on the role of local therapies in patients with
regional and/or distant recurrences after curative treatment helped in
clarifying the possible role of local therapies (including SBRT) in this
patient subset [60]. As pointed out by the authors, interest in ablative
metastasis-directed therapies for recurrent/metastatic prostate cancer
emerged after the introduction of novel imaging modalities (for
example choline Positron Emission Tomography, PET) that
increased the detection of oligometastic patients, potentially justifying
a local approach either with or without systemic treatments. Fifteen
single-arm case series were identified with a total of 450 patients. In
most of the patients (98%), oligometastatic recurrence was diagnosed
through choline-PET co-registered with computed tomography
scans. Nodal, bone and visceral metastases were treated in 78%, 21%
and 1% of the patients, respectively. Patients were treated with either
RT (66%) or lymph node dissection (34%). Adjuvant androgen
deprivation was used for 61% of patients. In the case of nodal metas-
tases, prophylactic nodal irradiation was administered in 49% of
patients. Overall, 51% of patients were progression free at 1–3 years
after local therapies, with most of them receiving adjuvant treatment.
For SBRT, Grade 2 toxicity was observed in 8.5% of patients, and
there was one case of Grade 3 toxicity. For lymph node dissections,
11% and 12% of Grade 2 and Grade 3 complications, respectively,
were reported.
Of the 15 studies, six used SBRT as a metastasis-directed therapy
[61–66]. Casamassima et al. [61] reported on a series of 25 patients
with nodal metastases, with a median follow-up time of 24 months
that PFS at 3 years was 17%. Seven patients also received prophylactic
nodal irradiation. Muacevic et al. [62] described the results of SBRT
to bone metastases only in 40 patients, with a median follow-up of 14
months. The median PFS was not reached, and 75% of the patients
were alive at 17.5 months. In the series by Ahmed et al., 15 patients
received SBRT for bone metastases, 1 for nodal metastasis and 1 for
liver metastasic, with a median PFS of 12 months. Most of the
patients also received adjuvant androgen deprivation therapy [63].
Jereczek-Fossa et al. reported on a series of 34 oligorecurrent patients
(including recurrent primary), with a median follow-up time of 16.9
months; the median PFS was not reported (42.6% at 30 months)
[64]. The two series by Schick et al. [65] and Decaestecker et al. [66]
included patients with nodal, bone and visceral metastases. The first
study, retrospective on 50 patients, reported a median time to distant
recurrence of 15.6 months; the latter prospective, again including 50
patients, reported this time as 57.6 months. Median PFS was not
reached (58.6% at 3 years) in the first study, and it was 19 months in
the second. The median follow-up times were very similar (31 and 25
months, respectively). A recent multi-institutional analysis on oligo-
metastatic treatment-naïve patients was conducted with the aim of
estimating the potential benefit of SBRT in terms of distant PFS,
reducing the heterogeneity by pooling individual patient data from
various studies. In total, 163 metastases were treated in 119 patients.
The median distant PFS was 21 months, and no Grade 3 or more tox-
icity occurred. Given this result, the authors concluded that SBRT is
safe and associated with a prolonged distant PFS [67].
Table 3 summarizes the results of the reported studies on the use
of SBRT for oligometastatic/oligorecurrent prostate cancer.
The interpretation of these results is complex due to the extreme
heterogeneity of the reported series, and no conclusions can be
drawn on the role of SBRT. What emerged is that SBRT is a safe,
low-toxic treatment, in comparison with surgery, and its potential in
delaying progression is high. Again, as for other cancer subtypes, pro-
spective studies are needed to validate this hypothesis.
FUTURE PERSPECTIVES
Identifying patients who are most likely to benefit from metastasis-
directed radiation therapy is probably the most significant challenge,
as well as obtaining high quality prospective data on treatment effi-
cacy [7]. As the LCR achievable with either surgery or stereotactic
radiotherapy has increased over time, with acceptable toxicity, it is
important to select those patients who will have the maximal benefit.
Currently, oligometastatic patients are defined eligible for local ther-
apies through the use of clinical variables extracted from retrospective
series, such as the number of metastases, the disease-free interval, the
tumor type, the control of the primary tumor, the possibility of using
efficient systemic therapies (e.g. for oncogene-driven lung cancer)
and the presence of specific biological features (for example estrogen-
receptor positivity for breast cancer). Most of these criteria are the
same as those used to select patients for lung or liver surgery. Intra-
cranial involvement, traditionally considered a worse prognostic
factor, may not be interpreted the same in the era of radiosurgery to
multiple intracranial sites [68]. However, these relatively simple clin-
ical criteria appear insufficient for proper patient selection, being sur-
rogates for the tumor’s biology. Research efforts have been made to
correlate biological markers with clinical outcomes. A study on
resected pulmonary metastases and of the combination of primary
and metastatic tumors has identified a microRNA signature that may
select patients whose disease is unlikely to progress rapidly [69]. The
same group showed that, when restricted to lung metastases, micro-
RNA signatures are able not only to classify patients as oligo versus
polymetastatic but also to differentiate those patients with a low
recurrence probability following surgical resection [70]. These
studies need a prospective validation, but represent a significant step
forward in the identification of biomarkers in this setting. Other
researchers focused their attention on metabolic response after abla-
tive therapy: one study showed that only 10% of patients with a
partial response on first post-radiotherapy PET, and 29% of those in
complete response, progressed during follow-up [71]. In metastatic
breast cancer, circulating tumor cells (CTCs) showed the potential to
be a powerful predictive toll for response to systemic therapy [72].
Theoretically, CTCs might also be used as a powerful biomarker for
both evaluating the presence of a true oligometastatic state and pre-
dicting outcome after ablative therapies. The eradication of previously
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Table 3. Studies investigating the use of SBRT in oligometastatic prostate cancer
Study Patients Eligibility criteria Study design Site of
metastases
Therapy Median
follow-up
(months)
Median PFS
(months)
Median OS (months) Other therapy
(percentage)
Casamassima
et al. [61]
25 nodal recurrence only retrospective
observational
lymph nodes SBRT 29 PFS rate at
3 years 17%
OS rate at 3 years 92% NR
Muacevic et al.
[62]
40 bone metastases prospective bone SBRT 14 NR not reached (75% alive
at 17.5 months)
chemotherapy
(20%), previous
RT (20%), ADT
(47.5%)
Ahmed et al.
[63]
17 <5 metastases retrospective
observational
bone, lymph
nodes, liver
SBRT 6 12 NR (cancer-specific
survival 100% at
12 months)
Jereczek-Fossa
et al. [64]
34 recurrent primary, node
or metastatic
retrospective
observational
nodal SBRT 16.9 NR (30 months
PFS 42.6%)
NR ADT (55%)
Schick et al. [65] 50 synchronous or
metachronous
oligometastases
retrospective
observational
lymph nodes,
bone,
visceral
SBRT 31 3-year PFS
(clinical)
58.6%
NR (OS at 3 years 92%) ADT (100%)
Decaestecker
et al. [66]
50 oligorecurrent
metastatic, <3 lesions
prospective
observational
lymph nodes,
bone,
visceral
SBRT 24 19 NR (androgen
deprivation–free
survival 25 months)
ADT (70%)
Ost et al. [67] 119 <3 metastases,
treatment-naive,
recurrent
pooled analysis of
individual patient
data
lymph nodes,
bone,
visceral
SBRT 36 21 NR (OS at 5 years 88%) ADT (50%)
SRS = stereotactic radiosurgery, SBRT = stereotactic body radiation therapy, PFS = progression-free survival, OS = overall survival, ADT = androgen deprivation therapy, NA = not applicable, NR = not reported.
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detectable CTCs could indicate that the primary source of CTCs was
the treated lesions and not occult sites reseeding [7].
The need for prospective controlled studies has been already dis-
cussed for the various examined histologies; currently, a significant
number of clinical trials in different diseases are exploring the effect
of SBRT in terms of better PFS, prolongation of the time interval
‘free’ from systemic treatments, or even OS. All these efforts will be
crucial for elucidating the exact role of SBRT in oligometastatic
disease, and their result are awaited with great anticipation.
CONCLUSIONS
SBRT appears a safe and efficient way to treat oligometastases from
different primary tumors, with very high LCRs and low toxicity. Due
to the predominant nature of existing data, mainly retrospective, and
the intrinsic heterogeneity and complexity of this population, there
are still doubts about the wide application of SBRT in clinical prac-
tice. However, as for surgery, the encouraging results obtained so far
have increased the use of SBRT worldwide. In specific subpopula-
tions, we showed that there is a trend towards a significant improve-
ment in PFS and OS rates. Ongoing and future trials are warranted to
better establish its role, and important translational studies are
ongoing and we hope will provide us with very helpful information
about patient selection in the future.
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